Prophylactic anti-infective activity of poly-[1-6]-β-D-glucopyranosyl- [1-3]-β-D-glucopyranose glucan in a guinea pig model of staphylococcal wound infection

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 545-549

  Kernodle, Douglas S ^a,b,c   Gates, Hiriam ^a   Kaiser, Allen B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETAFECTIN; IMMUNOMODULATING AGENT; METICILLIN; POLY [1-6] BETA D GLUCOPYRANOSYL [1-3] BETA D GLUCOPYRANOSE GLUCAN; UNCLASSIFIED DRUG;

ABSCESS; ANIMAL CELL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; GUINEA PIG; IMMUNOMODULATION; INFECTION PREVENTION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; WOUND INFECTION;

EID: 0031894345     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.545     Document Type: Article

References (29)

1. Babineau, T. J., P. Marcello, W. Swails, A. Kenler, B. Bistrian, and R. A. Forse. 1994. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 220:601-609.
2. Babineau, T. J., A. Hackford, A. Kenler, B. Bistrian, R. A. Forse, P. G. Fairchild, S. Heard, M. Keroack, P. Caushaj, and P. Benotti. 1994. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. 129:1204-1210.
3. Bleicher, P., and W. Mackin. 1995. Betafectin® PGG-glucan: a novel carbohydrate immunomodulator with anti-infective properties. J. Biotechnology Healthcare Res. Reg. 2:207-222.
4. Brunke-Reese, D., Y. Gu, K. Crotty, L. Fisette, and W. M. Mackin. 1994. Enhanced microbicidal activities of human peripheral blood monocytes and neutrophiles (PMN) after pre-treatment with PGG-glucan (Betafectin™). FASEB J. 8:488.
5. Burke, J. F. 1961. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 50:161-168.
6. Cisneros, R. L., F. C. Gibson, and A. O. Tzianabos. 1996. Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis. Infect. Immun. 64:2201-2205.
7. Classen, D. C., R. S. Evans, S. L. Pestotnik, S. D. Horn, R. L. Menlove, and J. P. Burke. 1992. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N. Engl. J. Med. 326:281-286.
8. deFelippe, J. J., M. daRocha-Silva, F. M. Maciel, A. de M. Soares, and N. F. Mendes. 1993. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg. Gynecol. Obstet. 177:383-388.
9. Frank, M. O., and G. L. Mandell. 1995. Immunomodulators, p. 450-458. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
10. Gibson, F. C., III, A. O. Tzianabos, and A. B. Onderdonk. 1996. The capsular polysaccharide complex of Bacteroides fragilis induces cytokine production from human and murine phagocytic cells. Infect. Immun. 64:1065-1069.
11. Gold, H. S., and R. C. Moellering. 1996. Antimicrobial-drug resistance. N. Engl. J. Med. 335:1445-1453.
12. Jamas, S., D. D. Easson, Jr., and G. Ostroff. June 1994. U.S. patent 5,322,841.
13. Kaiser, A. B., D. S. Kernodle, and R. A. Parker. 1992. Low-inoculum model of surgical wound infection. J. Infect. Dis. 166:393-399.
14. Kernodle, D. S., and A. B. Kaiser. 1993. Comparative prophylactic efficacy of cefazolin and vancomycin in a guinea pig model of Staphytococcus aureus wound infection. J. Infect. Dis. 168:152-157.
15. Kernodle, D. S., and A. B. Kaiser. 1993. Efficacy of prophylaxis with β-lactams and β-lactam/β-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model. Antimicrob. Agents Chemother. 37:702-707.
16. Kernodle, D. S., and A. B. Kaiser. 1994. Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in an experimental model of staphylococcal wound infection. Antimicrob. Agents Chemother. 38:1325-1330.
17. Kernodle, D. S., and A. B. Kaiser. 1995. Postoperative infections and antimicrobial prophylaxis, p. 2742-2756. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Inc., New York, N.Y.
18. Lorenz, W., K.-P. Reimund, F. Weitzel, I. Celik, M. Kurnatowski, C. Schneider, W. Mannheim, A. Heiske, K. Neumann, H. Sitter, and M. Rothmund. 1994 Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. Surgery 116:925-934.
19. McCullagh, P., and J. A. Nelder. 1989. Generalized linear models, 2nd ed. Chapman and Hall, London, United Kingdom.
20. Miles, A. A., E. M. Miles, and J. Burke. 1957. The value and duration of defense mechanisms to the primary lodgement of bacteria. Br. J. Exp. Pathol. 38:79-86.
21. Nakao, A., H. Kato, T. Kanbe, K. Tanaka, H. Tamura, S. Tanaka, and H. Takagi. 1994. Quantitative assay (1-3)-β-D-glucan in culture media of Candida albicans using the G-test. Eur. J. Surg. Res. 26:194-200.
22. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved Standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
23. Onderdonk, A. B., R. L. Cisneros, P. Hinkson, and G. Ostroff. 1992. Antiinfective effect of poly-β1-6-glucotriosyl-β-1-3-glucopyranose glucan in vivo. Infect. Immun. 60:1642-1647.
24. Page, C. P., J. M. A. Bohnen, J. R. Fletcher, A. T. McManus, J. S. Solomkin, and D. H. Wittmann. 1993. Antimicrobial prophylaxis for surgical wounds. Guidelines for clinical care. Arch. Surg. 128:79-88.
25. Panlilio, A. L., D. H. Culver, R. P. Gaynes, et al. 1992. Methicillin-resistant Staphylococcus aureus in U. S. hospitals. Infect. Control Hosp. Epidemiol. 13:582-586.
26. Poutsiaka, D. D., M. Mengozzi, E. Vannier, B. Sinha, and C. A. Dinarello. 1993. Cross-linking of the β-glucan receptor on human monocytes results in interleukin-1 receptor antagonist but not interleukin-1 production. Blood 82:3695-3700.
27. Schaberg, D. R., D. H. Culver, and R. P. Gaynes. 1991. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91(Suppl. 3B):72S-75S.
28. Stashenko, P., C. Y. Wang, E. Riley, Y. Wu, G. Ostroff, and R. Niederman. 1995. Reduction of infection-stimulated periapical bone resorption by the biological response modifier PGG glucan. J. Dent. Res. 74:323-330.
29. Tzianabos, A. O., and R. L. Cisneros. 1996. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria. Ann. N. Y. Acad. Sci. 797:285-287.